Promise ahead: The role of inhaled insulin in clinical practice

Diabetes, Obesity and Metabolism, Supplement

Volumn 7, Issue 1, 2005, Pages

  Heine, Robert J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diabetes; Exubera ; Inhaled insulin

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

CLINICAL PRACTICE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRY POWDER; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHOBIA; REVIEW; TABLET;

EID: 27844540369     PISSN: 14657740     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. The Diabetes Control and Complications Trial Research Group (DCCT). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. Koro CE, Bowlin SJ, Bourgeois N et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004; 27: 17-20.
4. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am J Cardiol 1995; 75: 894-903.
5. Hayward RA, Manning WG, Kaplan SH et al. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA 1997; 278: 1663-1669.
6. Cryer PE. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 1999; 15: 42-46.
7. Zambanini A, Newson RB, Maisey M et al. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999; 46: 239-246.
8. Mollema ED, Snoek FJ, Heine RJ et al. Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening. Diabet Med 2001; 18: 671-674.
9. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1999; 22: S32-S41.
10. Turner RC, Cull CA, Frighi V et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
11. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 26 (Suppl. 3): S18-S24.
12. Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol 2003; 4: 661-667.
13. Cefalu WT, Skyler JS, Kourides IA et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001; 134: 203-207.
14. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004; 43: 781-801.
15. Sha S. The effect of smoking cessation on the absorption of inhaled insulin (Exubera). Diabetes Care 2002; 51: A133.
16. Henry RR, Mudaliar SR, Howland WC III et al. Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care 2003; 26: 764-769.
17. Scherbaum WA. Unlocking the opportunity of tight glycaemic control. Inhaled insulin: clinical efficacy. Diabetes Obes Metab 2005; 7(Suppl. 1): 9-13.
18. Quattrin T, Belanger A, Bohannon NJ et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2622-2627.
19. Skyler JS, Weinstock RS, Raskin P et al. Use of inhaled insulin in a basal/bolus insulin regimen in subjects with type 1 diabetes: a 6-month, randomized, comparative trial. Diabetes Care 2005; 28: 1630-1635.
20. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther 2004; 26: 1498-1505.
21. Rosenstock J, Cappelleri JC, Bolinder B et al. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004; 27: 1318-1323.
22. Freemantle N, Blonde L, Duhat D et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005; 28: 427-428.
23. Freemantle N, Gibson E, Bolinder B et al. Will availability of inhaled insulin improve management of type 2 diabetes? The Real World Trial. Clin Trials 2005; 2: S65-S66 [Abstract].